Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × ALT-803 × Breast × Clear all

Phase

Phase 1/2 3 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 5 Thoracic 4 Other hematologic neoplasm 3 Dermatologic 3 Head & Neck 2 Gynecologic 2 Gastrointestinal 2 Tumor-Agnostic 1 Plasma cell 1 Myeloid 1 Lymphoid 1 CNS 1 Breast 1

Conditions

Triple Negative Breast Neoplasms 1

Interventions

Trastuzumab 305 Paclitaxel 274 Cyclophosphamide 252 Docetaxel 240 Capecitabine 199 Carboplatin 188 Letrozole 163 Fulvestrant 162 Doxorubicin 147 Bevacizumab 126 Anastrozole 106 Tamoxifen 103 Vinorelbine 98 pembrolizumab 97 Gemcitabine 97 Epirubicin 95 pertuzumab 92 exemestane 90 Albumin-Bound Paclitaxel 82 Lapatinib 77 Radiotherapy 73 130-nm albumin-bound paclitaxel 72 palbociclib 67 eribulin 67 Cisplatin 60 Taxes 55 pyrotinib 54 Everolimus 49 Drug Therapy 44 Goserelin 43

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03554109 2025-02-21

TNBC

ImmunityBio, Inc.

Phase 2 Withdrawn

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡